NYTimes Quotes Dr. Gleicher on PGS

New York Times ran an extensive article on the alleged benefits of preimplantation genetic screening (PGS) in IVF cycles, quoting Dr. Gleicher. Proponents of PGS claim that screening embryos produced in IVF cycles for chromosomal abnormalities and transferring only the normal embryos improves IVF pregnancy chances and reduces miscarriage rates.

In the article, Dr. Gleicher explained that the rationale behind CHR’s vocal opposition to indiscriminate use of PGS for this purpose: there simply is no convincing data in the literature that PGS carries any of these benefits for most infertility patients, and extensive mosaicism in normal human embryos makes it practically impossible to tell whether an embryo is chromosomally normal or abnormal in a single-biopsy test. Unfortunately, the New York Times article gave–in our opinion–far too much space to PGS proponents in an attempt to provide “balanced” reporting.

Here is a list of recent PGS articles to learn more about why patients should carefully weigh the pros and cons of PGS before taking the plunge.

Norbert Gleicher, MD, leads CHR’s clinical and research efforts as Medical Director and Chief Scientist. A world-renowned reproductive endocrinologist, Dr. Gleicher has published hundreds of peer-reviewed papers and lectured globally while keeping an active clinical career focused on ovarian aging, immunological issues and other difficult cases of infertility.